{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:08:56Z","timestamp":1761523736698,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["113102004"],"award-info":[{"award-number":["113102004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.clcc.2016.09.002","type":"journal-article","created":{"date-parts":[[2016,9,18]],"date-time":"2016-09-18T16:30:21Z","timestamp":1474216221000},"page":"195-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A\u00a0Longitudinal Study"],"prefix":"10.1016","volume":"16","author":[{"given":"Felice N.","family":"van Erning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryska L.G.","family":"Janssen-Heijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes A.","family":"Wegdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit D.","family":"Slooter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"Wijsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Art","family":"Vreugenhil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonneke A.J.M.","family":"Beijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonneke V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery E.P.P.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2016.09.002_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib2","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2013.49.6638","article-title":"Impact of age on the efficacy of newer adjuvant therapies in patients with stage II\/III colon cancer: findings from the ACCENT database","volume":"31","author":"McCleary","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib3","first-page":"199","article-title":"Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience","volume":"13","author":"Kim","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib4","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2011.41.1140","article-title":"Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years","volume":"30","author":"Sanoff","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib5","article-title":"Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy","author":"Van Erning","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib6","unstructured":"National Working Group on Gastrointestinal Cancers, 2015. Available at: www.oncoline.nl. Accessed: September 11,\u00a02015."},{"key":"10.1016\/j.clcc.2016.09.002_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00001813-200409000-00005","article-title":"Peripheral neuropathy associated with capecitabine","volume":"15","author":"Saif","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clcc.2016.09.002_bib8","first-page":"18","article-title":"Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies","volume":"70","author":"Beijers","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.clcc.2016.09.002_bib9","first-page":"619","article-title":"Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies","volume":"12","author":"Ocean","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SPC.0b013e328342f9cc","article-title":"Chemotherapy-induced neuropathic pain","volume":"5","author":"Farquhar-Smith","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clcc.2016.09.002_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.12788\/jcso.0086","article-title":"Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy","volume":"12","author":"Beijers","year":"2014","journal-title":"J\u00a0Community Support Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib12","first-page":"1999","article-title":"A\u00a0systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib13","first-page":"9","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clcc.2016.09.002_bib14","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/annonc\/mds208","article-title":"Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients","volume":"23","author":"Argyriou","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/annonc\/mdp594","article-title":"Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?","volume":"21","author":"Storey","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.critrevonc.2013.08.009","article-title":"Oxaliplatin induced-neuropathy in digestive tumors","volume":"89","author":"Sereno","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clcc.2016.09.002_bib17","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib18","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1188\/10.CJON.E22-E28","article-title":"Patient perceptions associated with chemotherapy-induced peripheral neuropathy","volume":"14","author":"Tofthagen","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clcc.2016.09.002_bib19","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","article-title":"The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts","volume":"47","author":"van de Poll-Franse","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/art.10993","article-title":"The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research","volume":"49","author":"Sangha","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clcc.2016.09.002_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11764-015-0429-z","article-title":"The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry","volume":"9","author":"Vissers","year":"2015","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.clcc.2016.09.002_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1185\/03007995.2015.1014030","article-title":"Observational study of adjuvant therapy with capecitabine in colon cancer","volume":"31","author":"Steffens","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clcc.2016.09.002_bib25","first-page":"2575","article-title":"Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer","volume":"24","author":"Murugan","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib26","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2016.09.002_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3816\/SCT.2004.n.013","article-title":"Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies","volume":"1","author":"Clark","year":"2004","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.clcc.2016.09.002_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u201chand-foot\u201d) syndrome: incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clcc.2016.09.002_bib29","first-page":"625","article-title":"The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA","volume":"20","author":"Wolf","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2016.09.002_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients","volume":"25","author":"Schmoll","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib31","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","article-title":"Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07","volume":"25","author":"Land","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib32","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/0284186X.2014.980912","article-title":"Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry","volume":"54","author":"Beijers","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib34","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1158\/1078-0432.CCR-12-0205","article-title":"Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy","volume":"18","author":"Boyette-Davis","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2016.09.002_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3122\/jabfm.17.5.309","article-title":"The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients","volume":"17","author":"Mold","year":"2004","journal-title":"J\u00a0Am Board Fam Pract"},{"key":"10.1016\/j.clcc.2016.09.002_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Gutierrez-Gutierrez","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clcc.2016.09.002_bib37","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/bjc.2014.496","article-title":"The impact of low-grade toxicity in older people with cancer undergoing chemotherapy","volume":"111","author":"Kalsi","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300281630175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300281630175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:04:40Z","timestamp":1761519880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300281630175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S153300281630175X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2016.09.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A\u00a0Longitudinal Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2016.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}